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Westminster Hospital, London, UKAbstractThe Q80K polymorphism in the hepatitis C virus (HCV) NS3 enzyme reduces susceptibility to simeprevir and other novel protease inhibitors.
The aims of this study were to determine the prevalence of Q80K in treatment-naïve HCV-1a carriers in the North West region (NW) and
South East region (SE) of England, investigate the occurrence of Q80K as a minority variant, and characterize viral phylogeny. Plasma samples
from subjects who were naïve to anti-HCV therapy were subjected to conventional (Sanger) and deep (Illumina-Miseq, 1% interpretative cut-
off) sequencing of NS3. Q80K occurred in 44 of 238 subjects (18.5%, 95% CI 13.6–23.4%), including 19 of 70 (27.1%) in the NW and 25 of 168
(14.9%) in the SE (p 0.0425), with no difference in HCV RNA load or human immunodeﬁciency virus (HIV) status. Q80K frequencies in reads of
samples subjected to Illumina sequencing were >40% in all cases. Among subjects with Q80K, ﬁve of 44 (11.4%) showed one additional major
resistance-associated mutation in NS3, detected at frequencies of >10% (V36L and V55A) or <10% (V36M). Phylogenetic analyses identiﬁed the
two recognized HCV-1a lineages with (clade I) and without (clade II) Q80K. Overall, 148 of 238 (62.2%) sequences occurred within regional or
inter-regional clusters, each comprising 3–20 sequences. There was no unique clustering of English sequences relative to strains from
continental Europe and North America. In conclusion, Q80K was found at a high prevalence among treatment-naïve HCV-1a carriers in
England, and was reliably detected by conventional sequencing, with no increased detection by deep sequencing. English sequences were
highly interspersed with sequences from elsewhere in Europe (clade II) and North America (clade I), and their phylogeny was consistent
with multiple introductions from different areas.
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degree of genetic variability, and only 47% of its amino acids are
conserved among circulating HCV genotypes [1]. NS3 genetic
heterogeneity and the associated molecular and structural dif-
ferences inﬂuence HCV susceptibility to protease inhibitors
(PIs), including licensed ﬁrst-generation (telaprevir and boce-
previr) and second-generation (simeprevir) compounds. HCV
variants with reduced PI susceptibility have been observed inClin Microbiol Infect 2015; 21: 1033–1039
linical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved
http://dx.doi.org/10.1016/j.cmi.2015.07.017
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to lysine substitution at codon 80 (Q80K) reduces susceptibility
to simeprevir in vitro [2,4,11], and was also seen to reduce
virological responses to simeprevir plus pegylated interferon-α
and ribavirin in clinical studies [12–14]. Screening for Q80K is
therefore recommended before treatment with simeprevir is
started [15].
The prevalence of Q80K among PI-naïve subjects varies by
HCV genotype and subtype. An analysis of global NS3 se-
quences deposited in GenBank reported Q80K in 42% of HCV-
1a strains, and also detected a high prevalence in HCV-5 and
HCV-6 strains [1]. Among HCV-1a strains, the prevalence of
Q80K ranges between 3% and 47% by geographical location,
exceeding 40% in North America [2,4]. The reported preva-
lence is 20% overall across Europe, although it differs markedly
by country [7–9]. Most studies to date have produced preva-
lence estimates by using conventional (Sanger) sequencing,
which allows detection of virus variants present at a frequency
of 20% within a patient’s sample.
This study had three aims. The ﬁrst was to determine the
prevalence of Q80K in NS3 sequences obtained from HCV-1a
carriers attending for care in two regions of England. The
second aim was to investigate the occurrence of Q80K as a
low-frequency variant by deep sequencing, and thereby to both
gain insights into the viral quasi-species and determine whether
conventional sequencing offers sufﬁcient sensitivity for
screening simeprevir candidates for the presence of Q80K. The
third aim was to determine the phylogeny of NS3 sequences in
relation to publically available sequences from the rest of
Europe and North America.Materials and methodsStudy population
The study was performed retrospectively with stored plasma
samples from consecutive adults who, in 2006–2014, atten-
ded for care at the Royal Liverpool University Hospital in
Liverpool (North-West region (NW)) and at King’s College
Hospital, Chelsea & Westminster Hospital, and Charing
Cross Hospital in London (South-East region (SE)). Eligible
patients were infected with HCV-1a according to the geno-
typing method available at the local National Health System
diagnostic laboratory; the assignment was conﬁrmed by
analysis of the NS3 sequences produced in this study. Pa-
tients were naïve to all anti-HCV therapy. Human immuno-
deﬁciency virus (HIV) status and HCV RNA load were
retrieved from the clinics’ databases. Ethics permission to
conduct the study after the removal of personal identiﬁersClinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infectfrom the samples was granted by the South Berkshire
Regional Ethics Committee.
Sanger sequencing
HCV RNA was extracted with Nuclisens easyMAG (bio-
Mérieux, Basingstoke, UK), and cDNA synthesis was per-
formed with the Qiagen OneStep RT-PCR Kit (Qiagen, Hilden,
Germany), with forward primer 3278 (50-GGA-
GACCAAGMTCATCACSTGG-30) and reverse primer 4032
(50-GCTCTTRCCGCTGCCRGTGGG-30). The ﬁrst-round
amplicon was subjected to nested PCR with the Qiagen Hot-
StarTaq Kit, with forward primer 3307 (50-ACACCG-
CSGCGTGYGGKGACAT-30) and reverse primer 4014 (50-
GGRGCRTGYAGRTGGGCCAC-30). The second-round 727-
bp amplicon (amino acid 180 of NS2 to amino acid 204 of
NS3) was puriﬁed with the Qiagen QIAquick PCR Puriﬁcation
Kit, and sequenced with the BigDye Terminator Cycle
Sequencing Kit v3.1 on the ABI Prism 3730 Genetic Analyser
(Applied Biosystems, Paisley, UK). Consensus sequences were
assembled with SeqScape (v2.7) and analysed with the geno2-
pheno system (http://hcv.geno2pheno.org/index.php; March
2015 version) for the presence of HCV resistance-associated
mutations (RAMs).
Deep sequencing
HCV RNA was extracted with QiasymphonySP (Qiagen), by
use of the Qiagen DSPVirus/Pathogen Midi Kit and the Cell-
Free_500_V4 protocol; cDNA was produced with the ImProm
II Reverse Transcription System (Promega, Southampton, UK)
and random primers. NS3 was ampliﬁed with Q5 High-Fidelity
DNA Polymerase (New England Biolabs, Hitchin, UK) and the
above primers. PCR products were puriﬁed with AMPure XP
Beads (Beckman Coulter, High Wycombe, UK) before quanti-
ﬁcation with the Quant-iT dsDNA High Sensitivity Kit (Life
Technologies, Paisley, UK) on a Qubit 2.0 Fluorometer (Life
Technologies). The Nextera XT Sample Preparation Kit (Illu-
mina, Essex, UK) was used for library preparation, and pooled
amplicon libraries were sequenced on an Illumina MiSeq with v2
reagents. Data generation and initial analysis were carried out at
the Centre for Genomic Research at the University of Liver-
pool. Adapter sequences were trimmed from the Illumina reads
with Cutadapt v1.2.1 [16]; further trimming was performed
with Sickle v1.2 (http://github.com/najoshi/sickle), with applica-
tion of a minimum window quality score of 20. BAMStats
(http://sourceforge.net/projects/bamstats/ﬁles/) was used to
calculate the read statistics. Variants were analysed with the
VirVarSeq pipeline [17], which utilizes the quality of the run and
individual bases to ﬁlter poor-quality bases and reduce false-
positive rates. A 727-bp region of an HCV-1a molecular
clone encoding full-length NS3 was ampliﬁed and sequenced inious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 1033–1039
TABLE 1. Prevalence of NS3 resistance-associated mutations
(RAMs) in treatment-naïve hepatitis C virus-1a carriers
according to modality of detection (Sanger or Illumina) and
CMI Beloukas et al. Prevalence of Q80K in HCV-1a carriers in the UK 1035four replicates, in order to estimate the assay error rate. The
plasmid control yielded an average of 174 799 reads, with a
mean coverage of 46 268 reads per nucleotide. The mean error
rate, calculated by counting false substitution reads at the
codon level of the molecular clone [18], was 0.6% (standard
deviation 0.2%) over NS3 amino acids 1–181.
Phylogenetic analysis
Reference HCV-1a sequences and all available HCV-1a NS3
sequences from North America and Europe with conﬁrmed
genotype assignment and country of origin were retrieved from
the Los Alamos HCV database (hcv.lanl.gov/content/sequence/
HCV/ToolsOutline.html; accessed 8 March 2015) (Doc. S1). All
sequences, including those produced in this study (Sanger se-
quences and next-generation sequencing consensus sequences
with 1% interpretative cut-off) were aligned pairwise against the
HCV-1a reference genome H77 (accession no. NC_004102)
with MEGA v.6. The alignment was trimmed to codon positions
1–194 of NS3 (nucleotides 3421–4014 of H77). Sequences
with gaps or ambiguous nucleotides affecting 50% of the
targeted region or where codon 80 was missing or ambiguous
were removed (n = 3), yielding a total of 1162 NS3 sequences
for analysis. Two maximum-likelihood (ML) phylogenies were
estimated with and without codon 80, by use of a general time-
reversible nucleotide substitution model with gamma-
distributed among-site rate variation and the ML method as
implemented in PHYML v.3.0 [19,20]. Phylogenetic support was
evaluated with a bootstrap approach, and a total of 1000
bootstrap replicates were generated with FastTree v.2.1.7 [21];
local branch support was calculated with the Shimodaira–
Hasegawa-like test. Phylogenies were visualized and annotated
in FigTree (http://tree.bio.ed.ac.uk). Clusters (three or more
sequences) were identiﬁed by a bootstrap support of >75%, and
were deﬁned as regional if they comprised sequences unique to
either the NW or the SE, and inter-regional if they included
sequences from both regions.frequency of the mutant as determined by Illuminaa
RAMs
Sanger/Illumina >10%,
n (%)
Illumina 1–10%,
n (%)
Total tested 238 (100) 178 (100)
36 M 1 (0.4) 2 (1.1)
36 L 5 (2.1) 0 (0)
54 S 9 (3.8) 0 (0)
55 A 10 (4.2) 0 (0)
80 K 44 (18.5) 0 (0)
80 L 1 (0.4) 4 (2.2)
80 R 0 (0) 3 (1.7)
117 H 0 (0) 1 (0.6)
168 E 1 (0.4) 0 (0)
170 A 1 (0.4) 0 (0)
170 T 0 (0) 2 (1.1)
174 S 97 (40.8) 10 (5.6)
aRAMs were classiﬁed according to the geno2pheno mutation list (March 2015
version) with the addition of Q80L (Lenz et al. [11]). Bold indicates major mutationsStatistical analysis
Descriptive statistics were used to analyse the prevalence of
mutants in the study population (as the proportion of sub-
jects showing the mutation) and the frequency of mutants in
each patient’s sample (as the proportion of deep sequencing
reads showing the mutation). Proportions of subjects with
Q80K by geographical location and HIV status were
compared by the use of Fisher’s exact test. The Mann–
Whitney U-test was used to compare the HCV RNA loads of
patients with and without Q80K. The analysis was performed
with SPSS v.21.Clinical Microbiology and Infection © 2015 European Society of Clinical Microbiology anResultsStudy population
Overall, 238 adults (median age of 44 years, with no difference
by region) infected with HCV-1a were studied, including 70 of
238 (29.4%) in the NW and 168 of 238 (70.6%) in the SE. At the
time of testing, the median HCV RNA load was 6.3 log10 IU/mL
(interquartile range (IQR) 5.8–6.8), without differences be-
tween the two regions. Subjects were naïve to all anti-HCV
therapy. A total of 61 of 238 (25.6%) subjects, all from the
SE, were co-infected with HIV.
Q80K prevalence by Sanger sequencing
Overall, Q80K was detected in 44 of 238 subjects, yielding a
prevalence of 18.5% (95% CI 13.6–23.4%) (Table 1). Samples
from two of the 44 subjects had a mixed ﬁrst base at codon 80
(Q80Q/K). The median HCV RNA load was 6.4 log10 IU/mL
(IQR 5.8–6.7) vs. 6.3 log10 IU/mL (IQR 5.8–6.8) in samples
with vs. samples without Q80K, respectively (p 0.63). The
prevalence of Q80K was 19 of 70 (27.1%) in the NW and 25 of
168 (14.9%) in the SE (p 0.043). When results were compared
by HIV status in the SE, Q80K prevalence rates were 18 of 107
(16.8.%) in HCV-mono-infected subjects and seven of 61
(11.5%) in HCV/HIV-co-infected subjects (p 0.379). Table 1
shows other major and minor NS3 RAMs detected by Sanger
sequencing.
Q80K prevalence by deep sequencing
A total of 178 of 238 (74.8%) samples were subjected to deep
sequencing, comprising 28 of 178 (15.7%) with and 150 of 178
(84.3%) without Q80K by Sanger sequencing. An average offor genotype 1/1a.
d Infectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 1033–1039
FIG. 1. Phylogenetic analysis of hepatitis C virus (HCV) genotype 1a
NS3 sequences from the UK, where green indicates sequences from the
North West region of England, and yellow indicates sequences from the
South-East region of England. The global reference dataset was derived
from the Los Alamos HCV database (March 2015; see Doc. S1 for
accession numbers), and comprises sequences from the rest of Europe
(in red) and North America (in blue). Nodes with bootstrap support
values of 90% are indicated by asterisks.
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40 740–70 255), with an average coverage per nucleotide of
16 107. The prevalence of Q80K was 27 of 178 (15.2%; 95% CI
9.9–20.5%). All 28 samples showing Q80K by Sanger
sequencing also showed it by deep sequencing, usually (26 of 28
samples) with mutant frequencies of 98%. Of the two samples
showing Q80Q/K by Sanger sequencing, one had a Q/K ratio of
54: 46, and the other showed a Q/K/L ratio of 57: 41: 2. Of 150
samples lacking Q80K by Sanger sequencing, none showed it by
deep sequencing when an interpretative cut-off of 1% was
applied for the frequency of mutants within the reads, as usually
recommended [22]. The prevalence rates of Q80K increased
when the interpretative cut-off was lowered, and were three of
150 (2%) for Q80K occurring at a frequency between 0.5%
and <1%, and 15 of 150 (10%) for Q80K occurring at a fre-
quency between 0.2% and <0.5%. These cut-offs, however,
fell within the estimated error rate of the assay (0.6%; standard
deviation 0.2%).
Deep sequencing (interpretative cut-off of 1%) identiﬁed
additional NS3 RAMs that had not been observed with Sanger
sequencing and that occurred at frequencies between 1% and
6% (Table 1). Among the 44 subjects with Q80K, four of 44
(9.1%) had one additional major NS3 RAM at a frequency of
>10%, including V36L in three of 44 (6.8%) and V55A in one of
44 (2.3%). In addition, one of 44 (2.3%) subjects had V36M
detected only by Illumina, at a frequency of 3%.
Phylogeny of NS3 sequences
HCV-1a strains could be separated into the two recognized
distinct lineages with and without Q80K [23,24]. The sequences
harbouring Q80K at a frequency of <1% did not align with the
Q80K lineage (data not shown). There was no unique clustering
of the study English sequences (Fig. 1); rather, the sequences
were interspersed with sequences from the rest of Europe and
North America, and the phylogeny was consistent with multiple
introductions from different areas. For the English sequences,
four NW, eight SE and 11 inter-regional clusters were identi-
ﬁed, each consisting of 3–20 sequences (Fig. 2). In total, 148 of
238 (62.2%) sequences (49/70 (70.0%) in the NW; 99/168
(58.9%) in the SE) were circulating as regional or inter-regional
clusters.DiscussionThis study detected a high prevalence of the NS3 polymorphism
Q80K among treatment-naïve HCV-1a carriers attending for
care in England, particularly in the NW, where the prevalence
reached 27.1%. Previously published data from the UK include a
small cohort of 38 HIV-positive patients with acute HCV-1aClinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infectinfection, 16% of whom had Q80K [6]. A larger study ana-
lysed 159 subjects with HCV-1a who were enrolled in phase II/
III studies of telaprevir and simeprevir, 23% of whom had Q80K
[8]; these sequences are not available for analysis, however, as
they have not yet been deposited in the GenBank or the Los
Alamos database. These data indicate that HCV-1a strains
circulating in the UK have the highest prevalence of Q80K
observed in Europe.
In this study, the prevalence of Q80K varied by geographical
region, while showing no difference by HIV status. Prevalence
rates also show marked geographical variability in the rest of
Europe [7–9]. The variable prevalence has not been linked to
race or ethnicity [8], but, rather, is consistent with the circu-
lation of two distinct HCV-1a lineages with and without Q80Kious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 1033–1039
FIG. 2. A hepatitis C virus (HCV)
transmission cluster in the South East
region of England, comprising 20 HCV-1a
NS3 sequences (in yellow). Sequences
from the rest of Europe and North
America are shown in red and blue,
respectively. Nodes with bootstrap sup-
port values of 90% are indicated by
asterisks.
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nated in the USA in the 1940s [23]. In this study, the ML
phylogenetic analysis conﬁrmed the presence of the two HCV-
1a lineages, and detected multiple introductions of the two
lineages into the UK, with wide interspersal of the English
strains with other European and North American strains.
However, most HCV-1a sequences occurred as regional or
mixed regional clusters, suggesting that, for this cohort, the
majority of transmission events occurred within the UK.
The deep sequencing analysis showed that Q80K mutants
occurred at a high frequency (>40%) in the patients’ samples,
allowing detection by conventional sequencing in all cases. This
ﬁnding is consistent with the observation that Q80K mutants
have a replication capacity similar to that of the wild-type virus,
which allows transmissibility and persistence at high frequency
within the viral quasi-species, despite the absence of drug se-
lective pressure. There were no samples showing Q80K at a
frequency below the detection threshold of Sanger sequencing
(10–20%) and above the typical 1% interpretative cut-off
for deep sequencing, which is recommended to differentiate
biologically meaningful mutations from those caused by meth-
odological errors [22]. When less stringent cut-offs (0.5% or
0.2%) were applied, the proportion of samples showing Q80K
by deep sequencing increased. A previous study similarly found
that, among 21 subjects with Q80K detected by deep
sequencing, four showed the mutation at a frequency of <1%
[10]. The estimated error rate of the assay (0.6%) and the
observation that sequences showing Q80K at a frequency of
<1% did not align within the Q80K lineage suggest that theClinical Microbiology and Infection © 2015 European Society of Clinical Microbiology andetection of Q80K at a frequency of <1% was spurious.
Furthermore, it remains to be determined whether any Q80K
variant occurring at a low frequency has clinical relevance.
Q80K reduces HCV-1a susceptibility to simeprevir by 8-11
fold in vitro [4,8,11]. In HCV-1a infection, sustained virological
responses (SVR) to combination therapy with simeprevir plus
pegylated interferon-α and ribavirin are reduced by the pres-
ence of baseline Q80K in both treatment-naïve subjects (from
84% to 58%) and prior relapsers (from 79% to 47%) [11–13].
The impact of Q80K on the combination of simeprevir and
sofosbuvir was not immediately apparent in some reported
studies [25]. However, a phase III, open-label, single-arm study
with simeprevir plus sofosbuvir in cirrhotic patients with HCV-
1 recently reported that sustained virological response rates
were higher in subjects without Q80K (92%) than in those with
Q80K (74%) (Lawitz et al., 50th Annual Meeting of the Euro-
pean Association for the Study of the Liver, 2015). Q80K has
no effects on susceptibility to telaprevir and boceprevir [4], but
may have an effect on responses to asunaprevir [26]. Q80K
also confers small reductions (approximately three-fold) in
susceptibility to faldaprevir and paritaprevir in vitro, without
necessarily affecting response rates [27]. Q80L and Q80R were
detected in some subjects, usually at low frequencies. Their
signiﬁcance is unclear. In vitro, the mutations confer two-fold
and seven-fold reductions in susceptibility to simeprevir,
respectively [11]. Q80R has also been observed in a small
number of patients experiencing failure of simeprevir therapy,
when it occurred alongside major resistance mutations at po-
sition 155 and/or position 168 [28]. Other major NS3 RAMsd Infectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 1033–1039
1038 Clinical Microbiology and Infection, Volume 21 Number 11, November 2015 CMIoccurred at codons 36, 54, 55, 168, and 170, which is
consistent with previous observations [1–6,9,29]. A small
subset of ﬁve subjects had Q80K plus one other major RAM in
NS3.
In summary, we found a high prevalence of Q80K in HCV-1a
carriers with and without HIV accessing care in two regions of
the UK, thus complementing estimates from elsewhere in
Europe. Although deep sequencing increased detection of
Q80K, mutants missed by Sanger sequencing occurred at a
frequency of 0.5%, and detection seemed likely to be a
technical artefact. There was evidence of a high degree of
interspersal of UK sequences with sequences from elsewhere
in Europe and North America, although the phylogeny indicated
that most transmission events occurred in the UK. Investigation
of full viral genomes will elucidate HCV-1a transmission net-
works and provide data to inform control strategies.Transparency declarationThe authors declare that they have no conﬂicts of interest.AcknowledgementsThe work was supported by research awards from the British
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